Retroviruses and Autoimmunity

Internal Medicine

Volumn 40, Issue 2, 2001, Pages 80-86

  Sekigawa, Iwao ^a   Ogasawara, Hitoshi ^b   Kaneko, Hiroshi ^b   Hishikawa, Takashi ^b   Hashimoto, Hiroshi ^b  

^a JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

Human endogenous retrovirus; Human immunodeficiency virus; Systemic lupus erythematosus

Indexed keywords

GLYCOPROTEIN GP 120; MESSENGER RNA; VIRUS DNA; VIRUS RNA;

AUTOIMMUNE DISEASE; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMORBIDITY; ENDOGENOUS RETROVIRUS; ENVELOPE GENE; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; PROVIRUS; RETROVIRUS; RETROVIRUS INFECTION; REVIEW; STRUCTURAL GENE; SYSTEMIC LUPUS ERYTHEMATOSUS; VIROLOGY;

AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMORBIDITY; DNA, VIRAL; ENDOGENOUS RETROVIRUSES; GENES, ENV; GENES, GAG; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROVIRUSES; RETROVIRIDAE; RETROVIRIDAE INFECTIONS; RNA, MESSENGER; RNA, VIRAL;

EID: 0035257904     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.40.80     Document Type: Review

References (75)

1. Herrmann M, Hagenhofer M, Kalden JR. Retroviruses and systemic lupus erythematosus. Immunol Rev 152: 145-156, 1996.
2. Nakagawa K, Harrison LC. The potential roles of endogenous retroviruses in autoimmunity. Immunol Rev 152: 193-236, 1996.
3. Urnovitz HB, Murphy WH. Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease. Clin Microbiol Rev 9: 72-99, 1996.
4. Sekigawa I, Kaneko H, Hishikawa T, et al. HIV infection and SLE: their pathogenic relationship. Clin Exp Rheumatol 16: 175-180, 1998.
5. Repaske R, Steele PE, O'Neill RR, Rabson AB, Martin MA. Nucleotide sequence of a full-length human endogenous retroviral segment. J Virol 54: 764-772, 1985.
6. Löwer R. The pathogenic potential of endogenous retroviruses: facts and fantasies. Trends Microbiol 7: 350-356, 1999.
7. Löwer R, Löwer J, Kurth R. The viruses in all of us: characteristic and biological significance of human endogenous retrovirus sequences. Proc Natl Acad Sci USA 93: 5177-5184, 1996.
8. Tristem M. Identification and characterization of novel human endogenous retrovirus families by phylogenetic screening of the human genome mapping project database. J Virol 74: 3715-3730, 2000.
9. Fanning T, Alves G. A family of repetitive DNA sequences in old world primates. Gene 199: 279-282, 1997.
10. Leib-Mosch C, Bachmann M, Brack-Werner R, Werner T, Erfle V, Hehlmann R. Expression and biological significance of human endogenous retroviral sequences. Leukemia 6 Suppl 3: 72s-75s, 1992.
11. Kitamura M, Maruyama N, Shirasawa T, et al. Expression of an endogenous retroviral gene product in human placenta. Int J Cancer 58: 836-840, 1994.
12. Yoshiki T, Mellors RC, Strand M, August JT. The viral envelope glycoprotein of murine leukemia virus and the pathogenesis of immune complex glomerulonephritis of New Zealand mice. J Exp Med 140: 1011-1027, 1974.
13. Shirai T, Ohta K, Kohno A, et al. Naturally occurring antibody response to DNA is associated with the response to retroviral gp70 in autoimmune New Zealand mice. Arthritis Rheum 29: 242-250, 1986.
14. Wu J, Zhou T, He J, Mountz JD. Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene. J Exp Med 178: 461-468, 1993.
15. Mellors RC, Mellors JW. Antigen related to mammalian type-C RNA viral p30 proteins is located in renal glomeruli in human systemic lupus erythematosus. Proc Natl Acad Sci USA 73: 233-237, 1976.
16. Rucheton M, Graafland H, Fanton H, Ursule L, Ferrier P, Larsen CJ. Presence of circulating antibodies against gag-gene MuLV proteins in patients with autoimmune connective tissue disorders. Virology 144: 468-480, 1985.
17. Query CC, Keene JD. A human autoimmune protein associated with U1 RNA contains a region of homology that is cross-reactive with retroviral p30 gag antigen. Cell 51: 211-220, 1987.
18. Talal N, Garry RF, Schur PH, et al. A conserved idiotype and antibodies to retroviral proteins in systemic lupus erythematosus. J Clin Invest 85: 1866-1871, 1990.
19. Brookes SM, Pandolfino YA, Mitchell TJ, et al. The immune response to and expression of cross-reactive retroviral gag sequences in autoimmune disease. Br J Rheumatol 31: 735-742, 1992.
20. Blomberg J, Nived O, Pipkorn R, Bengtsson A, Erlinge D, Sturfelt G. Increased antiretroviral antibody reactivity in sera from a defined population of patients with systemic lupus erythematosus: correlation with autoantibodies and clinical manifestations. Arthritis Rheum 37: 57-66, 1994.
21. Herrmann M, Kalden JR. PCR and reverse dot hybridization for the detection of endogenous retroviral transcripts. J Virol Methods 46: 333-348, 1994.
22. Koshino K, Tokano Y, Hishikawa T, Sekigawa I, Takasaki Y, Hashimoto H. Detection of antibodies to HIV-1 gp41 and HLA class II antigen-derived peptides in SLE patients. Scand J Rheumatol 24: 288-292, 1995.
23. Hishikawa T, Ogasawara H, Kaneko H, et al. Detection of antibodies to a recombinant gag protein derived from human endogenous retrovirus like sequence, clone 4-1, in autoimmune diseases. Viral Immunol 10: 137-147, 1997.
24. Tamura N, Sekigawa I, Hashimoto H, Yamamoto N, Kira S. Syncytial cell formation in vivo by type C retroviral particles in the systemic lupus erythematosus (SLE) lung. Clin Exp Immunol 107: 474-479, 1997.
25. Cianciolo GJ, Copeland TD, Oroszlan S, Synderman R. Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science 230: 453-455, 1985.
26. Ruegg CL, Monell CR, Strand M. Inhibition of lymphoproliferation by a synthetic peptide with sequence identity to gp41 of human immunodeficiency virus type 1. J Virol 63: 3257-3260, 1989.
27. Haraguchi S, Good RA, Cianciolo GJ, Engelman RW, Day NK. Immunosuppressive retroviral peptides: immunopathological implications for immunosuppressive influences of retroviral infections. J Leukoc Biol 61: 654-666, 1997.
28. Kaye BR. Rheumatologic manifestations of infection with human immunodeficiency virus (HIV). Ann Intern Med 111: 158-167, 1989.
29. + T cells and deficient interleukin-2 production in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 55: 285-296, 1990.
30. + T cell function by the HIV envelope protein gp120. J Immunol 141: 3715-3717, 1988.
31. Rosenstein Y, Burakoff SJ, Herrmann SH. HIV-gp120 can block CD4-class II MHC-mediated adhesion. J Immunol 144: 526-531, 1990.
32. Breen EC, Rezai AR, Nakajima K, et al. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol 15: 480-484, 1990.
33. + T-cell clones. J Virol 65: 6277-6282, 1991.
34. Banda NK, Bernier J, Kurahara DK, et al. Crosslinking CD4 by human immunodeficiency virus gp120 primers T cells for activation-induced apoptosis. J Exp Med 176: 1099-1106, 1992.
35. lck in human CD4 lymphocytes. Eur J Immunol 23: 600-607, 1993.
36. Macchia D, Almerigogna F, Parronchi P, Ravina A, Maggi E, Romagnani S. Membrane tumor necrosis factor-α is involved in the polyclonal B-cell activation induced by HIV-infected human T cells. Nature 363: 464-466, 1993.
37. lck activation and TCR desensitization independent of TCR tyrosine phosphorylation. J Immunol 153: 2905-2917, 1994.
38. Ameglio F, Capobianchi MR, Castilletti C, et al. Recombinant gp120 induces IL-10 in resting peripheral blood mononuclear cells: correlation with the induction of other cytokines. Clin Exp Immunol 95: 455-458, 1994.
39. Sekigawa I, Koshino K, Hishikawa T, et al. Inhibitory effect of the immunosuppressant FK506 on apoptotic cell death induced by HIV-1 gp120. J Clin Immunol 15: 312-317, 1995.
40. Karsten V, Gordon S, Kirn A, Herbein G. HIV-1 envelope glycoprotein gp120 down-regulates CD4 expression in primary human macrophages through induction of endogenous tumor necrosis factor-α. Immunology 88: 55-60, 1996.
41. + T cell anergy. Clin Exp Immunol 109: 41-46, 1997.
42. Romagnani S, Del Prete G, Manetti R, et al. Role of TH1/TH2 cytokines in HIV infection. Immunol Rev 140: 73-92, 1994.
43. Barcellini W, Rizzardi GP, Borghi MO, et al. In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus: lack of relationship with clinical disease activity. Lupus 5: 139-145, 1996.
44. Bisset LR, Rothen M, Joller-Jemelka HI, Dubs RW, Grob PJ, Opravil M. Change in circulating levels of the chemokines macrophage inflammatory proteins 1α and 1β, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir. AIDS 11: 485-491, 1997.
45. Kaneko H, Ogasawara H, Naito T, et al. Circulating levels of β-chemokines in systemic lupus erythematosus. J Rheumatol 26: 568-573, 1999.
46. Neoh LP, Akimoto H, Kaneko H, et al. The production of β-chemokines induced by HIV-2 envelope glycoprotein. AIDS 11: 1062-1063, 1997.
47. Sekigawa I, Kaneko H, Neoh L-P, et al. Differences of HIV envelope protein between HIV-1 and HIV-2: possible relationship to the lower virulence of HIV-2. Viral Immunol 11: 1-8, 1998.
48. Sekigawa I, Groopman JE, Allan JD, et al. Characterization of autoantibodies to the CD4 molecule in human immunodeficiency virus infection. Clin Immunol Immunopathol 58: 145-153, 1991.
49. Lenert G, Lenert P. CD4-reactive antibodies from SLE patients induced reversible inhibition of polyclonal T lymphocyte proliferation. Hum Immunol 49: 113-121, 1996.
50. Sekigawa I, Lee S, Kaneko H, et al. The possible role of interleukin-16 in the low incidence of HIV infection in patients with systemic lupus erythematosus. Lupus 9: 155-156, 2000.
51. Lee S, Kaneko H, Sekigawa I, Tokano Y, Takasaki Y, Hashimoto H. Circulating IL-16 in systemic lupus erythematosus. Br J Rheumatol 37: 1334-1337, 1998.
52. Center DM, Kornfeld H, Cruikshank WW. Interleukin 16 and its function as a CD4 ligand. Immunol Today 17: 476-481, 1996.
53. Maciaszek JW, Parada NA, Cruikshank WW, Center DM, Kornfeld H, Viglianti GA. IL-16 represses HIV-1 promoter activity. J Immunol 158: 5-8, 1997.
54. + T cells. Immunology 96: 215-219, 1999.
55. + T cells and their derived cytokine, IL-16, in SLE. Autoimmunity 2000 (in press).
56. Taruscio D, Manuelidis L. Integration site preferences of endogenous retroviruses. Chromosoma 101: 141-156, 1991.
57. Taruscio D, Mantovani A. Eleven chromosomal integration sites of a human endogenous retrovirus (HERV 4-1) map close to known loci of thirteen hereditary malformation syndromes. Teratology 54: 108-110, 1996.
58. Ogasawara H, Hishikawa T, Sekigawa I, Hashimoto H, Yamamoto N, Maruyama N. Sequence analysis of human endogenous retrovirus clone 4-1 in systemic lupus erythematosus. Autoimmunity 2000 (in press).
59. Karpas A, Lowdell M, Jacobson SK, Hill F. Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK506. Proc Natl Acad Sci USA 89: 8351-8355, 1992.
60. Groudine M, Eisenman R, Weintraub H. Chromatin structure of endogenous retroviral genes and activation by an inhibitor of DNA methylation. Nature 292: 311-317, 1981.
61. Yung RL, Quddus J, Chrisp CE, Johnson KJ, Richardson BC. Mechanisms of drug-induced lupus. I. cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J Immunol 154: 3025-3035, 1995.
62. Horwitz DA, Stohl W, Gray JD. T lymphocyte, natural killer cells, cytokines, and immune regulation, in: Dubois' Lupus Erythematosus. 5th ed. Wallance DJ, Harn BH, Eds. Williams & Wilkins, Baltimore, 1997; 155-194.
63. Perron H, Garson JA, Bedin F, et al. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The collaborative research group on multiple sclerosis. Proc Natl Acad Sci USA 94: 7583-7588, 1997.
64. Rigby SP, Griffiths DJ, Weiss RA, Venables PJ. Human retrovirus-5 proviral DNA is rarely detected in salivary gland biopsy tissues from patients with Sjögren's syndrome. Arthritis Rheum 40: 2016-2021, 1997.
65. + T cell ratio and T cell activation in systemic lupus erythematosus. Scand J Rheumatol 28: 166-170, 1999.
66. Linker-Israeli M, Gray JD, Quismorio FP Jr, Horwitz DA. Characterization of lymphocytes that suppress IL-2 production in systemic lupus erythematosus. Clin Exp Immunol 73: 236-241, 1988.
67. Linker-Israeli M, Quismorio FP Jr, Horwitz DA. Further characterization of interleukin-2 production by lymphocytes of patients with systemic lupus erythematosus. J Rheumatol 15: 1216-1222, 1988.
68. Suh WK, Cohen-Doyle MF, Fruh K, Wang K, Peterson PA, Williams DB. Interaction of MHC class I molecules with the transporter associated with antigen processing. Science 264: 1322-1326, 1994.
69. Mingari MC, Moretta A, Moretta L. Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. Immunol Today 19: 153-157, 1998.
70. Hayashi T, Lee S, Ogasawara H, et al. Exacerbation of systemic lupus erythematosus related to cytomegalovirus infection. Lupus 7: 561-564, 1998.
71. Farrell HE, Vally H, Lynch DM, et al. Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo. Nature 386: 510-514, 1997.
72. Ogasawara H, Kaneko H, Hishikawa T, et al. Molecular mimicry between human endogenous retrovirus clone 4-1 and HLA class I antigen: with reference to the pathogenesis of systemic lupus erythematosus. Rheumatology 38: 1163-1164, 1999.
73. Fujinami RS, Libbey JE. Endogenous retroviruses: are they the cause of multiple sclerosis? Trends Microbiol 7: 263-264, 1999.
74. Iwakura Y, Tosu M, Yoshida E, et al. Induction of inflammatory arthropathy resembling rheumatoid arthritis in mice transgenic for HTLV-1. Science 253: 1026-1028, 1991.
75. Takeuchi K, Katsumata K, Ikeda H, Minami M, Wakisaka A, Yoshiki T. Expression of endogenous retroviruses, ERV3 and λ4-1, in synovial tissues from patients with rheumatoid arthritis. Clin Exp Immunol 99: 338-344, 1995.